Table 2 Correlation between c-Myc and the clinicopathological characteristics in HCC tissues and adjacent tissues
Variables | Cases | c-Myc expression in HCC tissues | P value | c-Myc expression in adjacent tissues | P value | ||
|---|---|---|---|---|---|---|---|
Low | High | Low | High | ||||
Age(yrs) | |||||||
> =60 | 16 | 4(25.0%) | 12(75.0%) | 0.161 | 3(18.8%) | 13(81.2%) | 0.140 |
< 60 | 68 | 30(44.1%) | 38(55.9%) | 26(38.2%) | 42(61.8%) | ||
Sex | |||||||
Male | 68 | 29(42.6%) | 39(57.4%) | 0.403 | 21(30.9%) | 47(69.1%) | 0.148 |
Female | 16 | 5(31.3%) | 11(68.7%) | 8(50.0%) | 8(50.0%) | ||
HbsAg | |||||||
Positive | 72 | 30(41.7%) | 42(58.3%) | 0.586 | 25(34.7%) | 47(65.3%) | 0.925 |
Negative | 12 | 4(33.3%) | 8(66.7%) | 4(33.3%) | 8(66.7%) | ||
ALT(U/L) | |||||||
≥ 80 | 9 | 3(33.3%) | 6(66.7%) | 0.644 | 5(55.6%) | 4(44.4%) | 0.160 |
<80 | 75 | 31(41.3%) | 44(58.7%) | 24(32.0%) | 51(68.0%) | ||
PLT(×109) | |||||||
> 100 | 74 | 33(44.6%) | 41(55.4%) | 0.036 | 24(32.4%) | 50(67.6%) | 0.273 |
≤ 100 | 10 | 1(10.0%) | 9(90.0%) | 5(50.0%) | 5(50.0%) | ||
Cirrhosis | |||||||
Yes | 64 | 22(34.4%) | 42(65.6%) | 0.042 | 19(29.7%) | 45(70.3%) | 0.095 |
No | 20 | 12(60.0%) | 8(40.0%) | 10(50.0%) | 10(50.0%) | ||
AFP(ug/L) | |||||||
≥ 20 | 48 | 22(45.8%) | 26(51.2%) | 0.248 | 19(39.6%) | 29(60.4%) | 0.260 |
<20 | 36 | 12(33.3%) | 24(66.7%) | 10(27.8%) | 26(72.2%) | ||
Tumor size (cm) | |||||||
≥ 5 | 50 | 25(50.0%) | 25(50.0%) | 0.031 | 19(38.0%) | 31(62.0%) | 0.416 |
<5 | 34 | 9(26.5%) | 25(73.5%) | 10(29.4%) | 24(70.6%) | ||
Tumor number | |||||||
Single | 62 | 21(33.9%) | 41(66.1%) | 0.038 | 20(32.3%) | 42(67.7%) | 0.463 |
Multiple | 22 | 13(59.1%) | 9(40.9%) | 9(40.9%) | 13(59.1%) | ||
Differentiation | |||||||
I-II | 62 | 24(38.7%) | 38(61.3%) | 0.580 | 25(40.3%) | 37(59.7%) | 0.061 |
III | 22 | 10(45.5%) | 12(54.5%) | 4(18.2%) | 18(81.8%) | ||
TNM stage | |||||||
I | 55 | 20(36.4%) | 35(63.6%) | 0.290 | 18(32.7%) | 37(67.3%) | 0.633 |
II-III | 29 | 14(48.3%) | 15(51.7%) | 11(37.9%) | 18(62.1%) | ||
PVTT | |||||||
Yes | 11 | 8(72.7%) | 3(27.3%) | 0.019 | 4(36.4%) | 7(63.6%) | 0.890 |
No | 73 | 26(35.6%) | 47(64.4%) | 25(34.2%) | 48(65.8%) | ||
Tumor Encapsulation | |||||||
Complete | 64 | 23(35.9%) | 41(64.1%) | 0.130 | 17(26.6%) | 47(73.4%) | 0.006 |
None | 20 | 11(55.0%) | 9(45.0%) | 12(60.0%) | 8(40.0%) | ||
Recurrence | |||||||
Yes | 58 | 30(51.7%) | 28(48.3%) | 0.002 | 21(36.2%) | 37(63.8%) | 0.628 |
No | 26 | 4(15.4%) | 22(84.6%) | 8(30.8%) | 18(69.2%) | ||
Complication | |||||||
No | 73 | 27(37.0%) | 46(63.0%) | 0.177 | 27(37.0%) | 46(63.0%) | 0.221 |
Yes | 11 | 7(63.6%) | 4(36.4%) | 2(18.2%) | 9(81.8%) | ||